AVXL
NASDAQAnavex Life Sciences Corp.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
News · 26 weeks40+200%
2026-03-012026-08-23
Mix2190d
- SEC Filings13(62%)
- Other6(29%)
- Leadership1(5%)
- Earnings1(5%)
Latest news
25 items- SECAnavex Life Sciences Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)
- PRAnavex Life Sciences Reports Third Fiscal Quarter 2026 Financial Results and Business UpdateClinical Development Strategy for Alzheimer’s Disease Remains the Focus as Anavex Advances Regulatory Progress Across All Three Programs Anavex Submits Completed Alzheimer’s Disease Clinical Study Data and Rett Syndrome Formal Meeting Request to FDA, with an IND Submission for Fragile X Syndrome Planned for September NEW YORK, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system ("CNS") diseases with high unmet medical needs, today reported a business update and financial results for its third fiscal quarter ended June 30, 20
- SECSEC Form DEFA14A filed by Anavex Life Sciences Corp.DEFA14A - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)
- SECSEC Form PRRN14A filed by Anavex Life Sciences Corp.PRRN14A - ANAVEX LIFE SCIENCES CORP. (0001314052) (Subject)
- SECSEC Form DEFA14A filed by Anavex Life Sciences Corp.DEFA14A - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)
- SECSEC Form DEFA14A filed by Anavex Life Sciences Corp.DEFA14A - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)
- SECAnavex Life Sciences Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)
- PRAnavex Life Sciences Mails Letter to Stockholders Reinforcing Relevant Experience of All Six Director NomineesLaunches VoteAnavex.com to Provide Additional Information on Anavex’s Director Nominees and How to Vote at the Annual Meeting of Stockholders NEW YORK, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system ("CNS") diseases with high unmet medical needs, today announced that the Executive Committee of the Anavex Board of Directors (the "Executive Committee") has mailed a letter to stockholders encouraging them to vote the WHITE proxy card "FOR" all six of Anavex’s highly qualified directors standing for election at the Company’s
- SECSEC Form DEFA14A filed by Anavex Life Sciences Corp.DEFA14A - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)
- SECAnavex Life Sciences Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)
- PRAnavex Life Sciences Highlights Highly Qualified Board and Decisive Actions to Create Long-Term Value for StockholdersFiles Definitive Proxy Statement and Mails Letter to Stockholders Urges Stockholders to Vote "FOR" All Six Anavex Director Nominees on the WHITE Proxy Card Underscores PVG’s Lack of Clear Plan and Inexperienced Slate of Director Nominees NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system ("CNS") diseases with high unmet medical needs, today announced that it has filed definitive proxy materials with the Securities and Exchange Commission ("SEC") in connection with its upcoming 2026 Annual Meeting of Stockholders
- SECSEC Form DEFC14A filed by Anavex Life Sciences Corp.DEFC14A - ANAVEX LIFE SCIENCES CORP. (0001314052) (Subject)
- SECSEC Form NT 10-Q filed by Anavex Life Sciences Corp.NT 10-Q - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)
- SECAnavex Life Sciences Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)
- PRAnavex Life Sciences Announces Plans to Refresh Board to Continue Overseeing Critical Progress and Stockholder Value CreationNominates Two New Independent Directors, Mr. Gautam Patel and Dr. Adrian Senderowicz, Who Bring Deep, Relevant Experience in Life Sciences Mr. Patel and Dr. Senderowicz to Stand for Election at 2026 Annual Meeting with Independent Directors Dr. Jiong Ma, Dr. Peter Donhauser, Dr. Axel Paeger and Dr. Claus van der Velden Urges Stockholders to Reject Attempt by PVG Asset Management Corporation and Patrick S. Adams to Acquire Control of the Company Issues Open Letter to Stockholders and Files Preliminary Proxy Statement NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on de
- SECSEC Form PREC14A filed by Anavex Life Sciences Corp.PREC14A - ANAVEX LIFE SCIENCES CORP. (0001314052) (Subject)
- SECAnavex Life Sciences Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)
- PRAnavex Life Sciences Reports Preliminary Second Quarter 2026 Financial Results and Provides Business UpdateNEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (Anavex or the Company) (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system (CNS) diseases with high unmet medical needs, today reported preliminary financial results for its fiscal second quarter ended March 31, 2026. The Company’s primary focus is on advancing its lead compound ANAVEX®2-73 (blarcamesine) in the Company’s clinical program for the treatment of mild cognitive impairment ("MCI") due to Alzheimer’s disease ("AD") and mild AD (collectively known as "early AD"), and for Rett syndrome and Fragile X syndrome, both of which are neurode
- SECSEC Form PREC14A filed by Anavex Life Sciences Corp.PREC14A - ANAVEX LIFE SCIENCES CORP. (0001314052) (Subject)
- SECAnavex Life Sciences Corp. filed SEC Form 8-K: Other Events8-K - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)
- SECAnavex Life Sciences Corp. filed SEC Form 8-K: Other Events8-K - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)
- SECAnavex Life Sciences Corp. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits8-K - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)
- PRAnavex Life Sciences Receives Expected Nasdaq Delinquency NotificationNEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system (CNS) disorders, today announced it received an expected delinquency notification letter (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") on May 20, 2026. The Notice indicates that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Nasdaq Listing Rule") as a result of the Company's inability to timely file its Form 10-Q for the quarterly period ended March 31, 2026. As indicated in the Notice
- SECAnavex Life Sciences Corp. filed SEC Form 8-K: Leadership Update8-K - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)
- INSIDERSEC Form 3 filed by new insider Kellmeyer Terrie3 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)
AVXL FAQ
6 questionsWhat does Anavex Life Sciences Corp. do?
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The...Where does AVXL stock trade?
Anavex Life Sciences Corp. (AVXL) is listed on NASDAQ.What sector and industry is AVXL in?
Anavex Life Sciences Corp. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What are analysts saying about AVXL?
Anavex Life Sciences Corp. has had 6 recent analyst actions on file. The most recent action was from Rodman & Renshaw: Buy with a $2000.00 price target on 2026-05-04. Recent price targets range from $1100.00 to $4200.00.What companies are similar to AVXL?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare AVXL side-by-side with any of them on Quantisnow.How can I track AVXL on Quantisnow?
Quantisnow aggregates Anavex Life Sciences Corp.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AVXL to receive live email and push alerts on every new disclosure.